People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

Surgery is the gold standard, GLP-1s are all the rage—whether a head-to-head study is needed depends on who you ask.

The Centers for Medicare & Medicaid Services announced 15 new drugs it wants to lower the cost for, including popular, but ...

A recent study reveals many websites selling compounded versions of weight-loss drugs do not inform users of risks, often ...

New Activin R-based medications can emerge as perfect solutions for balancing weight loss and muscle building, making a ...

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

Medicare to negotiate prices for blockbuster drugs like Ozempic and Wegovy, potentially saving enrollees millions.

Drugmakers will have until the end of February to decide whether they want to participate in the second round of Medicare ...

GLP-1 drugs used for weight loss involve all kinds of side effects—good and not-so-good—that may or may not strike the ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...